Therefore, additional research examining whether the VP2 peptide can act as a vector facilitating the transfer of chemotherapeutics or act as an inhibitor of the VPAC1 receptor expressed in CRC and other cancer cell lines will be performed with the aim of developing VP2 as a novel targeting probe for the treatment of CRC and other tumors. The gene discussed is VIPR1; the disease is cancer.